Anti-NAT8L monoclonal antibody

Pre-made anti-NAT8L monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to NAT8L/NAT8L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1236-Ab-1/ GM-Tg-hg-IP1236-Ab-2Anti-Human NAT8L monoclonal antibodyHuman
GM-Tg-rg-IP1236-Ab-1/ GM-Tg-rg-IP1236-Ab-2Anti-Rat NAT8L monoclonal antibodyRat
GM-Tg-mg-IP1236-Ab-1/ GM-Tg-mg-IP1236-Ab-2Anti-Mouse NAT8L monoclonal antibodyMouse
GM-Tg-cynog-IP1236-Ab-1/ GM-Tg-cynog-IP1236-Ab-2Anti-Cynomolgus/ Rhesus macaque NAT8L monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1236-Ab-1/ GM-Tg-felg-IP1236-Ab-2Anti-Feline NAT8L monoclonal antibodyFeline
GM-Tg-cang-IP1236-Ab-1/ GM-Tg-cang-IP1236-Ab-2Anti-Canine NAT8L monoclonal antibodyCanine
GM-Tg-bovg-IP1236-Ab-1/ GM-Tg-bovg-IP1236-Ab-2Anti-Bovine NAT8L monoclonal antibodyBovine
GM-Tg-equg-IP1236-Ab-1/ GM-Tg-equg-IP1236-Ab-2Anti-Equine NAT8L monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1236-Ab-1/ GM-Tg-hg-IP1236-Ab-2; GM-Tg-rg-IP1236-Ab-1/ GM-Tg-rg-IP1236-Ab-2;
GM-Tg-mg-IP1236-Ab-1/ GM-Tg-mg-IP1236-Ab-2; GM-Tg-cynog-IP1236-Ab-1/ GM-Tg-cynog-IP1236-Ab-2;
GM-Tg-felg-IP1236-Ab-1/ GM-Tg-felg-IP1236-Ab-2; GM-Tg-cang-IP1236-Ab-1/ GM-Tg-cang-IP1236-Ab-2;
GM-Tg-bovg-IP1236-Ab-1/ GM-Tg-bovg-IP1236-Ab-2; GM-Tg-equg-IP1236-Ab-1/ GM-Tg-equg-IP1236-Ab-2
Products NameAnti-NAT8L monoclonal antibody
Formatmab
Target NameNAT8L
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-NAT8L monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1236-Ag-1Recombinant multi-species NAT8L/ CML3/ NACED protein


    Target information

    Target IDGM-IP1236
    Target NameNAT8L
    Gene ID339983,269642,289727,722359,612955,101083676,614317,100052893
    Gene Symbol and Synonyms1110038O08Rik,CML3,NACED,NAT8-LIKE,NAT8L,RGD1305719,Shati
    Uniprot AccessionQ8N9F0,D3ZVU9
    Uniprot Entry NameNAT8L_HUMAN,NAT8L_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000185818
    Target ClassificationN/A

    The target: NAT8L, gene name: NAT8L, also named as CML3, NACED, NAT8-LIKE. This gene encodes a single-pass membrane protein, which contains a conserved sequence of the GCN5 or NAT superfamily of N-acetyltransferases and is a member of the N-acyltransferase (NAT) superfamily. This protein is a neuron-specific protein and is the N-acetylaspartate (NAA) biosynthetic enzyme, catalyzing the NAA synthesis from L-aspartate and acetyl-CoA. NAA is a major storage and transport form of acetyl coenzyme A specific to the nervous system. The gene mutation results in primary NAA deficiency (hypoacetylaspartia). [provided by RefSeq, Dec 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.